Showing results (111-120 of 162) with videos related to
Sort By:
Pageof 17
Future Oncology (London, England)|February 23, 2023
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemiaChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.Blood|February 23, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohortConstantine S Tam, John N Allan, Tanya Siddiqi, et al.The Lancet. Oncology|September 13, 2024
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trialAlessandra Tedeschi, Anna Maria Frustaci, Adalgisa Condoluci, et al.Hematological Oncology|February 7, 2019
Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical networkSara Rattotti, Virginia Valeria Ferretti, Chiara Rusconi, et al.Leukemia & Lymphoma|February 5, 2015
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemiaAlessandra Tedeschi, Paola Picardi, Simone Ferrero, et al.Blood Advances|August 19, 2025
Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studiesConstantine S Tam, Mary Ann Anderson, Martin Simkovic, et al.Seminars in Hematology|May 22, 2025
Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathyShirley D'Sa, Jahanzaib Khwaja, Signy Chow, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE StudyWilliam G Wierda, John N Allan, Tanya Siddiqi, et al.Cancers|June 10, 2023
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter StudyFrancesca R Mauro, Diana Giannarelli, Clementina M Galluzzo, et al.Blood|July 12, 2019
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 studyStefano Luminari, Michele Merli, Sara Rattotti, et al.Pageof 17